Turning the tumor microenvironment into a self vaccine site

OncoImmunology

Volumn 1, Issue 6, 2012, Pages 989-991

  Nelson, Delia J ^a,b,c  

^a CURTIN UNIVERSITY   (Australia)

^b Western Australian Biomedical Research Institute   (Australia)

^c CURTIN UNIVERSITY   (Australia)

Author keywords

B cells; Immunotherapy; Inflammation; Innate immune cells; T cells; Tumor endothelia

Indexed keywords

CANCER VACCINE; CD40 ANTIBODY; INTERLEUKIN 2; INTERLEUKIN 21; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTATION; ARTICLE; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; ENDOTHELIUM; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INJECTION SITE; INNATE IMMUNITY; MACROPHAGE; MALIGNANT NEOPLASTIC DISEASE; MEMORY T LYMPHOCYTE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SELF VACCINE SITE; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 84886945448     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.20238     Document Type: Article

References (10)

1. + T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2. J Immunol 2003; 171:5051-63; PMID:14607902.
2. Nelson DJ, Mukherjee S, Bundell C, Fisher S, van Hagen D, Robinson BWS. Tumor progression despite efficient tumor antigen cross-presentation and effective "arming" of tumor antigen-specific CTL. J Immunol 2001; 166:5557-66; PMID:11313395.
3. + T-regulator cells. Eur Respir J 2009; 34:162-75; PMID:19251786; http://dx.doi.org/10.1183/09031936.00101008.
4. Marzo AL, Lake RA, Lo D, Sherman L, McWilliam A, Nelson D, et al. Tumor antigens are constitutively presented in the draining lymph nodes. J Immunol 1999; 162:5838-45; PMID:10229818.
5. Robinson BWS, Lake RA, Nelson DJ, Scott BA, Marzo AL. Cross-presentation of tumour antigens: evaluation of threshold, duration, distribution and regulation. Immunol Cell Biol 1999; 77:552-8; PMID:10571677; http://dx.doi.org/10.1046/j.1440-711.1999.00876.x.
6. Jackaman C, Cornwall S, Graham PT, Nelson DJ. CD40-activated B cells contribute to mesothelioma tumor regression. Immunol Cell Biol 2011; 89:255- 67; PMID:20628372; http://dx.doi.org/10.1038/icb.2010.88.
7. Jackaman C, Lew AM, Zhan Y, Allan JE, Koloska B, Graham PT, et al. Deliberately provoking local inflammation drives tumors to become their own protective vaccine site. Int Immunol 2008; 20:1467-79; PMID:18824504; http://dx.doi.org/10.1093/intimm/dxn104.
8. Jackaman C, Nelson DJ. Intratumoral interleukin-2/ agonist CD40 antibody drives CD4(+)-independent resolution of treated-tumors and CD4(+)-dependent systemic and memory responses. Cancer Immunol Immunother 2012; 61:549-60; PMID:22002241; http://dx.doi.org/10.1007/s00262-011-1120-5.
9. Jackaman C, Lansley S, Allan JE, Robinson BWS, Nelson DJ. IL-2/CD40-driven NK cells install and maintain potency in the anti-mesothelioma effector/ memory phase. Int Immunol 2012; PMID:22354912; http://dx.doi.org/10.1093/intimm/dxs005.
10. Hamzah J, Nelson D, Moldenhauer G, Arnold B, Hämmerling GJ, Ganss R. Vascular targeting of anti- CD40 antibodies and IL-2 into autochthonous tumors enhances immunotherapy in mice. J Clin Invest 2008; 118:1691-9; PMID:18398504; http://dx.doi.org/10.1172/JCI33201.